Fecal Microbiota Transplantation to Reverse Host-Related Determinants of Resistance to Anticancer Immunotherapy

Affiliations

¹ Department of Cancer Services, The Royal Marsden NHS Foundation Trust, London, United Kingdom.
² Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

Comment

Paolo Davide D'arienzo et al. Gastroenterology. 2024 Mar.

. 2024 Mar;166(3):535.

doi: 10.1053/j.gastro.2023.12.001. Epub 2023 Dec 6.

¹ Department of Cancer Services, The Royal Marsden NHS Foundation Trust, London, United Kingdom.
² Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

No abstract available

Comment on

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
Routy B, Lenehan JG, Miller WH Jr, Jamal R, Messaoudene M, Daisley BA, Hes C, Al KF, Martinez-Gili L, Punčochář M, Ernst S, Logan D, Belanger K, Esfahani K, Richard C, Ninkov M, Piccinno G, Armanini F, Pinto F, Krishnamoorthy M, Figueredo R, Thebault P, Takis P, Magrill J, Ramsay L, Derosa L, Marchesi JR, Parvathy SN, Elkrief A, Watson IR, Lapointe R, Segata N, Haeryfar SMM, Mullish BH, Silverman MS, Burton JP, Maleki Vareki S. Routy B, et al. Nat Med. 2023 Aug;29(8):2121-2132. doi: 10.1038/s41591-023-02453-x. Epub 2023 Jul 6. Nat Med. 2023. PMID: 37414899 Clinical Trial.